The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and ...

Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

In RAMP-204, avutometinib is being combined with the KRAS G12C inhibitor adagrasib in patients with KRAS G12C-mutated non-small cell lung cancer. Their higher priority is RAMP-203, which is using ...

Clinical validation of this combination has been demonstrated with the approval of adagrasib in KRASG12C-mutated CRC. Additionally, the phase 1 clinical trial evaluating QTX3034, an oral ...

Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I drugs for Uterine Cancer have an 80% phase transition ...

Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% ...